David M. Rubitski - Concepedia

Author

David M. Rubitski

Pfizer (United States)

Also Known As

David M. Rubitski, David Rubitski

Publications

627

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)

About

David M. Rubitski is an author at Pfizer (United States) specializing in medicine, gene expression, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	188
2	Health Sciences	1	1	36
3	Natural Sciences	1	1	152
4	Biomolecular Engineering	1	1	152
5	Cell Biology	1	1	152

David M. Rubitski

Publications

624

Citations

H-Index

Page 1

	Year	Citations
Selective Inhibition of Casein Kinase 1ϵ Minimally Alters Circadian Clock Period Kevin M. Walton, Katherine Fisher, David M. Rubitski, Journal of Pharmacology and Experimental Therapeutics	2009	177
Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing Romain Rouet, Benjamin A. Thuma, Marc D. Roy, Journal of the American Chemical Society Molecular BiologyAsialoglycoprotein Receptor LigandsGenome EngineeringCrisprAntisense Therapy	2018	152
Discovery of Two Clinical Histamine H <sub>3</sub> Receptor Antagonists: <i>trans</i> - <i>N</i> -Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and <i>trans</i> -3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]- <i>N</i> -(2-methylpropyl)cyclobutanecarboxamide (PF-03654764) Travis T. Wager, Betty Pettersen, Anne W. Schmidt, Journal of Medicinal Chemistry	2011	107
The 5-Hydroxytryptamine4 Receptor Agonists Prucalopride and PRX-03140 Increase Acetylcholine and Histamine Levels in the Rat Prefrontal Cortex and the Power of Stimulated Hippocampal θ Oscillations David E. Johnson, Elena M. Drummond, Sarah Grimwood, Journal of Pharmacology and Experimental Therapeutics	2012	57
Identification of Multiple 5-HT<sub>4</sub>Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease Michael A. Brodney, David E. Johnson, Aarti Sawant‐Basak, Journal of Medicinal Chemistry	2012	42
Casein Kinase 1δ/ε Inhibitor PF-5006739 Attenuates Opioid Drug-Seeking Behavior Travis T. Wager, Ramalakshmi Y. Chandrasekaran, Jenifer A. Bradley, ACS Chemical Neuroscience Opioid EpidemicDrug TargetPsychotropic MedicationCns Kinase InhibitorPharmacotherapy	2014	36
Identification of Phosphorylation Consensus Sequences and Endogenous Neuronal Substrates of the Psychiatric Risk Kinase TNIK Qi Wang, David M. Rubitski, Matthew M. Hayward, Journal of Pharmacology and Experimental Therapeutics	2015	36
Comparing molecular and computational approaches for detecting viral integration of AAV gene therapy constructs Elias M. Oziolor, Steven W. Kumpf, Jessie Qian, Molecular Therapy — Methods & Clinical Development	2023	17

Page 1